Zealand Pharma, which licenses approved and investigational peptide-based treatments for diabetes, raised $78 million by offering 4.4 million ADSs at $17.87.
Zealand Pharma plans to list on the Nasdaq under the symbol ZEAL. Morgan Stanley and Goldman Sachs acted as lead managers on the deal.
